Printer Friendly

HOECHST AUSTRALIAN SUBSIDIARY LICENSED FOR PAI-2 DNA BY CISTRON BIOTECHNOLOGY

 PINE BROOK, N.J., June 2 /PRNewswire/ -- Biotech Australia Pty., Ltd., a subsidiary jointly owned by Hoechst A.G. and Hoechst Australia Ltd., has been granted an exclusive U.S. license by Cistron Biotechnology, Inc. for a DNA patent to make, use and sell plasminogen activator inhibitor, PAI-2, protein.
 Financial terms of the contract were not revealed.
 Under the agreement, Biotech Australia will develop therapeutic uses of PAI-2 which has potential application in treatment of cancer, some bleeding disorders and as an anti-inflammatory agent. Biotech Australia will produce the protein using recombinant DNA and Behringwerke A.G., another Hoechst subsidiary, will conduct clinical trials.
 Biotech Australia is collaborating with Behringwerke in commercializing PAI-2 for human health.
 Cistron has obtained a cross license from Biotech Australia for development of diagnostic products.
 PAI-2 is a protein synthesized by white blood cells which acts to inhibit plasmin, an enzyme which dissolves blood clots, but also promotes tumor metastasis and inflammation. Thus, it is felt that PAI-2 could be useful in treating cancer and inflammatory diseases.
 Biotech Australia, located in Sydney, Australia, develops biotechnical products for human, veterinary and food diagnostic uses.
 Cistron's primary product area is immune response regulators known as lymphokines. The company manufactures and sells lymphokine assay kits to pharmaceutical companies, the government and academic institutions in the United States, Europe and the Far East for cancer, arthritis and other autoimmune disease research.
 -0- 6/2/93
 /CONTACT: Harold W. Smith of Cistron, 201-305-0244, or Graeme C. Woodrow, Ph.D. of Biotech Australia, 011-612-417-0271/


CO: Cistron Biotechnology, Inc. ST: New Jersey IN: MTC SU: LIC

TM-OS -- NY002 -- 4306 06/02/93 09:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 2, 1993
Words:273
Previous Article:IRVINE SENSORS ANNOUNCES 'SENSOR-ON-A-CHIP' PRODUCT
Next Article:VITAFORT INTERNATIONAL CORPORATION ANNOUNCES NEW MANAGEMENT
Topics:


Related Articles
CISTRON SEEKS TO RAISE $4 MILLION THROUGH PRIVATE PLACEMENT
U.S DISTRICT COURT DECIDES IN FAVOR OF CISTRON IN PATENT INFRINGEMENT SUIT
CISTRON PROFITABLE FOR FIFTH STRAIGHT YEAR
CISTRON BIOTECHNOLOGY SUES IMMUNEX CORP. OVER INTERLEUKIN-1b PATENT
CISTRON NET INCOME INCREASED IN THIRD QUARTER
PEPROTECH FILES CHAPTER 11 BANKRUPTCY PETITION
Cistron Sales Increase in First Quarter
Cistron Reports Second Quarter Results
Cistron Biotechnology Reports 3rd Quarter Results
Cistron Announces Preliminary Results of IL-1 Adjuvant Effects On Influenza Vaccine

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters